Literature DB >> 2789227

Transforming growth factors beta slow down cell-cycle progression in a murine interleukin-2 dependent T-cell line.

M Stoeck1, S Miescher, H R MacDonald, V Von Fliedner.   

Abstract

Transforming growth factors beta (TGF-beta) inhibit the growth of a variety of cell types, including lymphocytes. The immunosuppressive effects of TGF-beta have been attributed to the interference of these molecules with the interleukin-2 (IL-2)-driven component of lymphocyte proliferation. In order to elucidate in more detail the effects of TGF-beta on IL-2-induced proliferation, we investigated the effects of porcine transforming growth factor beta 1 and 2 (pTGF-beta 1 and 2) on the IL-2-driven proliferation of a murine IL-2-dependent T-lymphocyte line (CTLL). The results showed that pTGF-beta 1 and 2 decreased 3H-thymidine incorporation in CTLL cells in a dose-dependent fashion (maximum decrease of 75-85%). Combined-time kinetic analysis of the effects of pTGF-beta on 3H-thymidine incorporation, cell growth, and cell-cycle distribution (monitored as DNA content distribution) revealed that, in the first 48 h of culture, pTGF-beta 1 increased the doubling time from 11.4 to 19.2 h without significantly affecting the cell-cycle distribution of CTLL cells. After 96 h of culture in the presence of pTGF-beta 1, cells started to accumulate in G0/G1, although at this time point 30% of the pTGF-beta 1-treated cells were still in S-G2/M. Furthermore, during the first 48 h, neither the expression of the 55 kd chain of the IL-2 receptor (IL-2R) nor the expression of the transferrin receptor (TfR) was affected by TGF-beta. After 72 h of culture in the presence of pTGF-beta 1, the expression of the IL-2R and TfR was decreased. The data suggest that in CTLL cells TGF-beta initially slows the progression of cells in all phases of cell cycle. In addition, the initial TGF-beta-mediated decrease of IL-2-induced 3H-thymidine incorporation and cell proliferation in CTLL cells is not due primarily to downregulation of the IL-2R and/or TfR.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2789227     DOI: 10.1002/jcp.1041410111

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  6 in total

1.  Synergistic effect of indomethacin and bleomycin on tumor growth produced by activating antitumor immunity.

Authors:  R Matsushita; K Hattori; K Hayashi; H Iizasa; F Ichimura; E Nakashima
Journal:  Pharm Res       Date:  2001-02       Impact factor: 4.200

2.  In vivo regulation of transforming growth factor beta 1 transcription by immunotherapy: interleukin-2 impairs interferon-alpha-stimulated increase in steady-state mRNA levels of transforming growth factor beta 1.

Authors:  B Jahn; J Brieger; K Fenchel; P S Mitrou; L Bergmann
Journal:  Cancer Immunol Immunother       Date:  1994-05       Impact factor: 6.968

3.  Transforming growth-interacting factor (TGIF) regulates proliferation and differentiation of human myeloid leukemia cells.

Authors:  Rizwan Hamid; Stephen J Brandt
Journal:  Mol Oncol       Date:  2009-07-29       Impact factor: 6.603

4.  A transforming growth factor beta 2 (TGF-beta 2)-like immunosuppressive factor in amniotic fluid and localization of TGF-beta 2 mRNA in the pregnant uterus.

Authors:  D J Altman; S L Schneider; D A Thompson; H L Cheng; T B Tomasi
Journal:  J Exp Med       Date:  1990-11-01       Impact factor: 14.307

5.  Smad4-deficient T cells promote colitis-associated colon cancer via an IFN-γ-dependent suppression of 15-hydroxyprostaglandin dehydrogenase.

Authors:  Sung Hee Choi; Alex Y Huang; John J Letterio; Byung-Gyu Kim
Journal:  Front Immunol       Date:  2022-08-15       Impact factor: 8.786

6.  Evaluation of the potential of a new ribavirin analog impairing the dissemination of ovarian cancer cells.

Authors:  Anaïs Wambecke; Carine Laurent-Issartel; Johanne Leroy-Dudal; Florence Giffard; Fanny Cosson; Nadège Lubin-Germain; Jacques Uziel; Sabrina Kellouche; Franck Carreiras
Journal:  PLoS One       Date:  2019-12-11       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.